Manic Muses very kindly sent me notification of news of another Drug Company having to pay out big bucks over mis or incorrect branding.
This time it is for $1.6 Billion dollars and is Abbott Laboratories the makers of the drug Depakote.
The article reads…
“Abbott pleaded guilty to misbranding Depakote by promoting the drug to control agitation and aggression in patients with elderly dementia and to treat schizophrenia when neither use was approved by the Food and Drug Administration, the Justice Department said.” 1
You can read the full article here and I am very grateful to Manic Muses for giving me the heads up on this.
Over recent months I have become aware of a number of cases like this.
Additionally this same article also goes on to state…
“Separate from the DOJ settlement, Abbott agreed to pay 45 states a total of $100 million to resolve liability under the state consumer-protection laws.” 1
But what this writer wants to know is, “What is all of this going to cost us?”
The need for drug companies to disclose proper and accurate information is unquestionable. As is the need for them to operate ethically.
Likewise I wholeheartedly believe they should be held accountable when they are not.
BUT I am a realist and can’t help wondering just who will end up paying for all these fines and settlements?
Do you think that it will be the companies themselves?
Or will it, as I suspect, be us – the end-user? We who are in many ways held to ransom by our dependency on these seemingly incredibly over-priced medications?
It is an important and interesting question don’t you think? It is also one whose importance may well, I fear, be going to increase as I predict that now these cases have happened there will be several more similar ones to follow in their wake.
According to the article ‘Abbott earned about $13 billion from Depakote sales during the period investigated’1 ,
Well I have an idea for the governing bodies and legislators….
How about now fining all these companies all the profits gained from such dodgy practices and using the money to fund proper legislation capping the amount of profit margins pharmaceutical companies can enjoy from the design, production and marketing of prescription medication?